ECSP034823A - Combinación que comprende n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metilfenil}-4-(3-piridil)-2-pirimidin-amina, y un agente quimioterapéutico - Google Patents
Combinación que comprende n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metilfenil}-4-(3-piridil)-2-pirimidin-amina, y un agente quimioterapéuticoInfo
- Publication number
- ECSP034823A ECSP034823A EC2003004823A ECSP034823A ECSP034823A EC SP034823 A ECSP034823 A EC SP034823A EC 2003004823 A EC2003004823 A EC 2003004823A EC SP034823 A ECSP034823 A EC SP034823A EC SP034823 A ECSP034823 A EC SP034823A
- Authority
- EC
- Ecuador
- Prior art keywords
- methyl
- combination
- piperazino
- amine
- chemotherapeutic agent
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title abstract 3
- -1 4-METHYL-PIPERAZINO-METHYL Chemical class 0.000 title abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 206010052779 Transplant rejections Diseases 0.000 abstract 2
- 230000001154 acute effect Effects 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Abstract
Un método para el tratamiento de un animal de sangre caliente, en especial un ser humano, que tiene una enfermedad proliferativa o rechazo de trasplante agudo o crónico, el cual comprende administrar al animal una combinación que comprende: (a) N-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metilfenil}-4-(3-piridil)-2-pirimidin-amina, y (b) un agente quimioterapéutico seleccionado a partir de agentes antineoplásticos, en especial como se definen en la presente, y agentes efectivos en el tratamiento de rechazo de trasplante agudo o crónico; una combinación que comprende (a) y (b) como se definen anteriormente, y opcionalmente cuando menos un vehículo farmacéuticamente aceptable para su uso simultáneo, separado, o en secuencia, en particular para la demora de progreso o tratamiento de una enfermedad proliferativa, en especial una enfermedad de tumor sólido.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29142701P | 2001-05-16 | 2001-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP034823A true ECSP034823A (es) | 2003-12-24 |
Family
ID=23120246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2003004823A ECSP034823A (es) | 2001-05-16 | 2003-10-29 | Combinación que comprende n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metilfenil}-4-(3-piridil)-2-pirimidin-amina, y un agente quimioterapéutico |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US20040167134A1 (es) |
| EP (2) | EP2253319A1 (es) |
| JP (2) | JP4477303B2 (es) |
| KR (2) | KR20080091866A (es) |
| CN (1) | CN1700917B (es) |
| AT (1) | ATE359790T1 (es) |
| AU (1) | AU2002342335B2 (es) |
| BR (1) | BR0209647A (es) |
| CA (1) | CA2444867C (es) |
| CO (1) | CO5540315A2 (es) |
| CZ (1) | CZ299756B6 (es) |
| DE (1) | DE60219617T2 (es) |
| DK (1) | DK1392313T3 (es) |
| EC (1) | ECSP034823A (es) |
| ES (1) | ES2283570T3 (es) |
| HU (1) | HUP0400038A3 (es) |
| IL (1) | IL158274A0 (es) |
| MX (1) | MXPA03010401A (es) |
| NO (2) | NO325453B1 (es) |
| NZ (1) | NZ529145A (es) |
| PL (2) | PL392652A1 (es) |
| PT (1) | PT1392313E (es) |
| RU (1) | RU2318517C2 (es) |
| SI (1) | SI1392313T1 (es) |
| SK (1) | SK14042003A3 (es) |
| WO (1) | WO2002092091A1 (es) |
| ZA (1) | ZA200307665B (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE419239T1 (de) | 2000-10-20 | 2009-01-15 | Eisai R&D Man Co Ltd | Verfahren zur herstellung von 4-phenoxy chinolin derivaten |
| GB0201882D0 (en) * | 2002-01-28 | 2002-03-13 | Novartis Ag | Organic compounds |
| AU2007201056B2 (en) * | 2002-01-28 | 2010-06-10 | Hyks-Instituutti Oy | Treatment of rheumatoid arthritis using imatinib |
| GB0202874D0 (en) * | 2002-02-07 | 2002-03-27 | Novartis Ag | Organic compounds |
| AU2003248813A1 (en) * | 2002-07-05 | 2004-01-23 | Beth Israel Deaconess Medical Center | Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
| JPWO2004080462A1 (ja) | 2003-03-10 | 2006-06-08 | エーザイ株式会社 | ｃ−Ｋｉｔキナーゼ阻害剤 |
| US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| GB0311971D0 (en) * | 2003-05-23 | 2003-06-25 | Novartis Ag | Organic compounds |
| CN101337930B (zh) | 2003-11-11 | 2010-09-08 | 卫材R&D管理有限公司 | 脲衍生物的制备方法 |
| JP4834553B2 (ja) * | 2004-09-17 | 2011-12-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 医薬組成物 |
| US20060235006A1 (en) * | 2005-04-13 | 2006-10-19 | Lee Francis Y | Combinations, methods and compositions for treating cancer |
| WO2007015569A1 (ja) * | 2005-08-01 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を予測する方法 |
| EP1925676A4 (en) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR |
| ES2545076T3 (es) * | 2005-08-03 | 2015-09-08 | Novartis Ag | Uso del inhibidor de HDAC panobinostat para el tratamiento de mieloma |
| KR101354828B1 (ko) * | 2005-11-04 | 2014-02-18 | 와이어쓰 엘엘씨 | ｍＴＯＲ 저해자, 헤르셉틴, 및/또는 ＨＫＩ-272의항신생물성 조합 |
| JPWO2007052849A1 (ja) * | 2005-11-07 | 2009-04-30 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質とｃ−ｋｉｔキナーゼ阻害物質との併用 |
| RU2448708C3 (ru) * | 2006-05-18 | 2017-09-28 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое средство против рака щитовидной железы |
| CN1899616A (zh) * | 2006-07-20 | 2007-01-24 | 中国人民解放军军事医学科学院生物工程研究所 | 非受体酪氨酸激酶c－Abl特异性抑制剂的新用途 |
| US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| WO2008093855A1 (ja) | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | 未分化型胃癌治療用組成物 |
| KR101513326B1 (ko) | 2007-11-09 | 2015-04-17 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 항종양성 백금 착물의 병용 |
| MX2010008187A (es) * | 2008-01-29 | 2010-08-10 | Eisai R&D Man Co Ltd | Uso combinado de inhibidor de angiogenesis y taxano. |
| CA2725598C (en) * | 2008-06-17 | 2013-10-08 | Wyeth Llc | Antineoplastic combinations containing hki-272 and vinorelbine |
| TH121482A (th) | 2009-08-19 | 2013-02-28 | นางสาวปัณณพัฒน์ เหลืองธาตุทอง | องค์ประกอบทางเภสัชกรรมที่ประกอบด้วยอนุพันธ์ของควิโนลีน |
| AU2011270165B2 (en) | 2010-06-25 | 2015-12-24 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| WO2012144463A1 (ja) | 2011-04-18 | 2012-10-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| EP3444363B1 (en) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| RU2015115397A (ru) | 2012-12-21 | 2017-01-25 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Аморфная форма производного хинолина и способ его получения |
| ES2687968T3 (es) | 2013-05-14 | 2018-10-30 | Eisai R&D Management Co., Ltd. | Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib |
| KR20230043234A (ko) | 2014-08-28 | 2023-03-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
| LT3263106T (lt) | 2015-02-25 | 2024-01-10 | Eisai R&D Management Co., Ltd. | Chinolino darinių kartumo sumažinimo būdas |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| MX373231B (es) | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| CA2994925C (en) | 2015-08-20 | 2023-08-29 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| BR112019023064A2 (pt) | 2017-05-16 | 2020-06-09 | Eisai R&D Man Co Ltd | tratamento de carcinoma hepatocelular |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
| ATE28864T1 (de) | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| GB8517360D0 (en) | 1985-07-09 | 1985-08-14 | Erba Farmitalia | Substituted androsta-1,4-diene-3,17-diones |
| US4749713A (en) | 1986-03-07 | 1988-06-07 | Ciba-Geigy Corporation | Alpha-heterocycle substituted tolunitriles |
| US4978672A (en) | 1986-03-07 | 1990-12-18 | Ciba-Geigy Corporation | Alpha-heterocyclc substituted tolunitriles |
| DE3776880D1 (de) | 1986-11-21 | 1992-04-02 | Ciba Geigy Ag | Neue substituierte alkandiphosphonsaeuren. |
| IL86632A0 (en) | 1987-06-15 | 1988-11-30 | Ciba Geigy Ag | Derivatives substituted at methyl-amino nitrogen |
| US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| TW225528B (es) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| EP0666868B2 (en) | 1992-10-28 | 2006-06-14 | Genentech, Inc. | Use of anti-VEGF antibodies for the treatment of cancer |
| US5428040A (en) * | 1993-08-31 | 1995-06-27 | The Du Pont Merck Pharmaceutical Company | Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| ATE212993T1 (de) | 1995-07-06 | 2002-02-15 | Novartis Erfind Verwalt Gmbh | Pyrolopyrimidine und verfahren zu ihrer herstellung |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| WO1997030174A1 (en) * | 1996-02-20 | 1997-08-21 | Sloan-Kettering Institute For Cancer Research | Combinations of pkc inhibitors and therapeutic agents for treating cancers |
| HU228446B1 (en) | 1996-04-12 | 2013-03-28 | Warner Lambert Co | Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof |
| WO1997039135A1 (en) * | 1996-04-17 | 1997-10-23 | Board Of Regents, The University Of Texas System | Enhanced expression of transgenes |
| DE69734513T2 (de) | 1996-06-24 | 2006-07-27 | Pfizer Inc. | Phenylamino-substituierte tricyclische derivate zur behandlung hyperproliferativer krankheiten |
| DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
| WO1998010767A2 (en) | 1996-09-13 | 1998-03-19 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| US20020128240A1 (en) * | 1996-12-30 | 2002-09-12 | Bone Care International, Inc. | Treatment of hyperproliferative diseases using active vitamin D analogues |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| US20010051628A1 (en) * | 1998-05-04 | 2001-12-13 | H.-J. Su Huang | Methods to modulate the resistance of cells to apoptosis mediated by mutant epidermal growth factor receptors |
| WO2000009495A1 (en) | 1998-08-11 | 2000-02-24 | Novartis Ag | Isoquinoline derivatives with angiogenesis inhibiting activity |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| DK1140173T4 (da) | 1998-12-22 | 2013-06-10 | Genentech Inc | Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf |
| US6833373B1 (en) * | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| GB9903547D0 (en) | 1999-02-16 | 1999-04-07 | Novartis Ag | Organic compounds |
| PT1165085E (pt) | 1999-03-30 | 2006-10-31 | Novartis Ag | Derivados de ftalazina para tratar doencas inflamatorias |
| GB9907908D0 (en) * | 1999-04-07 | 1999-06-02 | Bataille Regis | Organic compounds |
| GB9911582D0 (en) * | 1999-05-18 | 1999-07-21 | Pharmacia & Upjohn Spa | Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound |
| AU7373600A (en) * | 1999-09-15 | 2001-04-17 | American Home Products Corporation | Method of potentiating chemotherapy and treating solid tumors |
| HK1049787B (en) * | 1999-10-01 | 2014-07-25 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| WO2001028993A2 (en) * | 1999-10-19 | 2001-04-26 | Merck & Co. Inc. | Tyrosine kinase inhibitors |
| TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| US7238525B2 (en) * | 2000-06-30 | 2007-07-03 | The Regents Of The University Of California | Strategy for leukemia therapy |
| AU2002211427A1 (en) * | 2000-10-05 | 2002-04-15 | Whitehead Institute For Biomedical Research | Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors |
| HUP0301276A2 (hu) * | 2000-10-06 | 2003-11-28 | Biomedicines, Inc. | Kombinációs terápia ösztrogénérzékeny betegségek kezelésére |
| ATE321556T1 (de) * | 2000-10-27 | 2006-04-15 | Novartis Pharma Gmbh | Behandlung gastrointestinaler stroma-tumoren |
| KR100848197B1 (ko) * | 2001-02-27 | 2008-07-24 | 노파르티스 아게 | 신호 전달 억제제 및 에포틸론 유도체를 포함하는 배합물 |
| JP4942297B2 (ja) * | 2002-10-25 | 2012-05-30 | ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド | 肺高血圧症の処置を目的としたｎ−｛５−［４−（４−メチルピペラジノメチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリジン−アミンの使用 |
| US8168621B2 (en) * | 2005-09-30 | 2012-05-01 | Endece, Llc | 6-substituted estradiol derivatives and methods of use |
| TW200740776A (en) * | 2006-02-06 | 2007-11-01 | Osi Pharm Inc | N-phenylbenzotriazolyl c-kit inhibitors |
| EP2285976A4 (en) * | 2008-05-15 | 2011-10-26 | Univ Southern California | ERCC-1 EXPRESSION AS A PROGNOSIS FOR CHEMOTHERAPEUTIC RESULTS |
-
2002
- 2002-05-15 KR KR1020087023228A patent/KR20080091866A/ko not_active Ceased
- 2002-05-15 CA CA2444867A patent/CA2444867C/en not_active Expired - Fee Related
- 2002-05-15 CN CN028093623A patent/CN1700917B/zh not_active Expired - Fee Related
- 2002-05-15 IL IL15827402A patent/IL158274A0/xx unknown
- 2002-05-15 RU RU2003135786/14A patent/RU2318517C2/ru not_active IP Right Cessation
- 2002-05-15 PT PT02743024T patent/PT1392313E/pt unknown
- 2002-05-15 PL PL392652A patent/PL392652A1/pl unknown
- 2002-05-15 EP EP10173158A patent/EP2253319A1/en not_active Withdrawn
- 2002-05-15 WO PCT/EP2002/005362 patent/WO2002092091A1/en not_active Ceased
- 2002-05-15 NZ NZ529145A patent/NZ529145A/en unknown
- 2002-05-15 MX MXPA03010401A patent/MXPA03010401A/es active IP Right Grant
- 2002-05-15 JP JP2002589008A patent/JP4477303B2/ja not_active Expired - Lifetime
- 2002-05-15 PL PL02368068A patent/PL368068A1/xx unknown
- 2002-05-15 CZ CZ20033098A patent/CZ299756B6/cs not_active IP Right Cessation
- 2002-05-15 AT AT02743024T patent/ATE359790T1/de not_active IP Right Cessation
- 2002-05-15 SI SI200230560T patent/SI1392313T1/sl unknown
- 2002-05-15 SK SK1404-2003A patent/SK14042003A3/sk not_active Application Discontinuation
- 2002-05-15 HU HU0400038A patent/HUP0400038A3/hu unknown
- 2002-05-15 KR KR10-2003-7014844A patent/KR20030094415A/ko not_active Abandoned
- 2002-05-15 AU AU2002342335A patent/AU2002342335B2/en not_active Ceased
- 2002-05-15 DE DE60219617T patent/DE60219617T2/de not_active Expired - Fee Related
- 2002-05-15 US US10/476,817 patent/US20040167134A1/en not_active Abandoned
- 2002-05-15 EP EP02743024A patent/EP1392313B1/en not_active Expired - Lifetime
- 2002-05-15 ES ES02743024T patent/ES2283570T3/es not_active Expired - Lifetime
- 2002-05-15 BR BR0209647-1A patent/BR0209647A/pt not_active IP Right Cessation
- 2002-05-15 DK DK02743024T patent/DK1392313T3/da active
-
2003
- 2003-10-01 ZA ZA200307665A patent/ZA200307665B/en unknown
- 2003-10-21 NO NO20034713A patent/NO325453B1/no not_active IP Right Cessation
- 2003-10-29 EC EC2003004823A patent/ECSP034823A/es unknown
- 2003-11-06 CO CO03098325A patent/CO5540315A2/es not_active Application Discontinuation
-
2007
- 2007-12-07 NO NO20076323A patent/NO20076323L/no not_active Application Discontinuation
-
2009
- 2009-04-14 US US12/423,079 patent/US20090202541A1/en not_active Abandoned
- 2009-12-11 JP JP2009281667A patent/JP2010059202A/ja not_active Ceased
-
2012
- 2012-07-17 US US13/551,079 patent/US20120283206A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP034823A (es) | Combinación que comprende n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metilfenil}-4-(3-piridil)-2-pirimidin-amina, y un agente quimioterapéutico | |
| CY2020003I2 (el) | Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn | |
| CR8181A (es) | Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer | |
| DE60126923D1 (de) | Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika | |
| AR018109A1 (es) | FORMULACIoN GALÉNICA ADMINISTRABLE POR VíA ORAL QUE PERMITE UNA ABSORCIoN MEJORADA DE PRINCIPIOS ACTIVOS, USO DE UN AGENTE MAJORADOR DE ABSORCIoN PARA PREPARAR UNA FORMA DE DOSIFICACIoN ADMINISTRABLE POR VíA ORAL Y PROCEDIMIENTO PARA PREPARAR DICHA FORMULACIoN GALÉNICA | |
| CA2534816A1 (en) | Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors | |
| ATE485833T1 (de) | Pharmazeutische zusammensetzungen, die die immunogenität von schwach immunogenen antigenen fördern | |
| CY1109087T1 (el) | Ενωση ιμιδαζο[4,5-c]πυριδινης και μεθοδος αντι-ιικης θεραπειας | |
| PL356784A1 (pl) | Substancja do zastosowania w leczeniu łuszczycy | |
| AR053984A1 (es) | Combinacion de un inhibidor de proteina cinasa src y un inhibidor bcr - abl para el tratamiento de enfermedades proliferativas | |
| BR0306732A (pt) | Tratamentos em combinação para doença alérgica compreendendo a administração de um anticorpo anti-ige e composto antialérgico | |
| TNSN06182A1 (en) | COMBINATION OF (a) N-{5-[4-(4-METHYL-PYPERAZINO-METHYL)-BENZOYLAMIDO] -2-METHYLPHENYL} -4-(3-PYRIDIL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND USE THEREOF | |
| FR2846327B1 (fr) | Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant. | |
| ITRM20040223A1 (it) | Medicamento per il trattamento delle infezioni fungine, in particolare dell'aspergillosi. | |
| EP1704863A3 (en) | Combination comprising N-5-4-(4-Methyl-Piperazino-Methyl-)Benzoyla Mido]-2-Methylphenyl -4-(3-Pyridyl)-2Phyrimidine-amine and a chemotherapeutic agent | |
| AR055072A1 (es) | Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical | |
| WO2006136391A3 (en) | Treatment of solid tumor disease with combinations comprising imatinib and an efflux pump inhibitor | |
| AR030660A1 (es) | Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12 | |
| BR0007395B1 (pt) | compostos de s-nitrosotióis como agentes para o tratamento de disfunções circulatórias. | |
| IT250215Y1 (it) | Cuscino perfezionato adatto in presenza di sintomatologie del trattocervicale | |
| RU2004124474A (ru) | Способ профилактики задержания последа у коров | |
| IT1310374B1 (it) | Teca per l'esposizione in sicurezza di oggetti. | |
| ES1049618Y (es) | Plataforma para el tratamiento y manipulacion de arboles, especialmente palmeras. | |
| IT1310212B1 (it) | Dispositivo di sicurezza per l'ancoraggio del carico all'interno diveicoli, in particolare di veicoli adibiti al trasporto funebre. | |
| NO20011327L (no) | Hudpleiemiddel i form av en emulsjon, fremgangsmåte for fremstilling av nevnte hudpleiemiddel, samt anvendelse deav |